Actively Recruiting
MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients
Led by West China Hospital · Updated on 2026-04-03
2000
Participants Needed
1
Research Sites
256 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single-center, prospective, single-arm interventional study with historical control, designed to evaluate the clinical value of a multidisciplinary team (MDT)-based decision-making umbrella decision model in elderly patients with lung cancer. A total of 2,000 patients aged 60-90 years with newly diagnosed non-small cell or small cell lung cancer will be enrolled. Each patient will undergo comprehensive geriatric assessment and receive an individualized treatment plan formulated by an MDT comprising thoracic surgeons, geriatricians, oncologists, pulmonologists, rehabilitation therapists, and radiologists. Treatment options include surgery, ablation, stereotactic body radiotherapy (SBRT), neoadjuvant immunochemotherapy, targeted therapy, and best supportive care. The primary outcome is 3-year progression-free survival (PFS). Secondary outcomes include overall survival, objective response rate, quality of life (EORTC QLQ-LC43), incidence of adverse events (CTCAE v5.0), and healthcare economics. Historical controls (2014-2024) will be extracted from hospital records and matched using propensity score matching. The study aims to establish a standardized MDT pathway to improve treatment outcomes and reduce risks in the geriatric lung cancer population.
CONDITIONS
Official Title
MDT-Based Umbrella Decision Model for Geriatric Lung Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 60 to 90 years.
- Histologically or cytologically confirmed non-small cell or small cell lung cancer.
- Clinical stage I-IV according to IASLC TNM staging.
- ECOG Performance Status 0-2.
- Estimated life expectancy of at least 3 months.
- Able to tolerate baseline examinations (CT, MRI, pulmonary function tests) and at least one planned treatment modality.
- Provide written informed consent and agree to complete full follow-up including questionnaires and assessments.
- Other conditions deemed suitable by the investigator.
You will not qualify if you...
- History of other primary malignancies within the past 5 years (except non-melanoma skin cancer or carcinoma in situ of the cervix).
- Unclear pathological diagnosis or pathological review excluding lung cancer post-enrollment.
- Severe psychiatric disorders or cognitive impairment (MMSE score less than 20) interfering with questionnaire completion or treatment decision communication.
- Contraindications to study-related examinations or treatments, including iodine-based contrast agents, MRI incompatibility, or severe allergies to essential therapeutic agents.
- Severe organ dysfunction preventing examinations or treatment tolerability.
- No fixed residence or contact information, or family refusal to assist with follow-up causing high dropout risk.
- Concurrent participation in another interventional lung cancer clinical trial (observational studies allowed).
- Any other condition judged by the investigator to make the patient unsuitable for participation.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
West China Hospital, Sichuan University
Chengdu, Sichuan, China, 610041
Actively Recruiting
Research Team
Y
Yu NA Tong, Master's degree
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here